Table 5. Antibiogram resultsa from pathogens identified from central line-associated bloodstream infections, 2015–2020.
| Antibiotic | Number of resistant/number tested and % | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-positive | Gram-negative | Fungi | ||||||||||||||
| Coagulase-negative staphylococcib | S. aureus c | Enterococcus spp. | Klebsiella spp. | E. coli | Enterobacter spp. | C. albicans | Candida spp. otherd | |||||||||
| # of resistant | % | # of resistant | % | # of resistant | % | # of resistant | % | # of resistant | % | # of resistant | % | # of resistant | % | # of resistant | % | |
| Ampicillin | 13/15 | 87 | N/A | N/A | 126/368 | 34 | 119/122 | 98 | 71/112 | 63 | 60/64 | 94 | N/A | N/A | N/A | N/A |
| Cefazolin | 167/193 | 87 | 16/120 | 13 | N/A | N/A | 35/95 | 37 | 29/92 | 32 | 55/56 | 98 | N/A | N/A | N/A | N/A |
| Ceftriaxone | 15/19 | 79 | 4/12 | 33 | N/A | N/A | 16/100 | 16 | 13/84 | 15 | 37/65 | 57 | N/A | N/A | N/A | N/A |
| Clindamycin | 159/305 | 52 | 31/126 | 25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Ciprofloxacin | N/A | N/A | N/A | N/A | N/A | N/A | 11/105 | 10 | 22/76 | 29 | 1/86 | 1 | N/A | N/A | N/A | N/A |
| Cloxacillin/Oxacillin | 306/351 | 87 | 32/218 | 15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Erythromycin | 77/91 | 85 | 17/64 | 27 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gentamicin | 20/39 | 51 | 1/25 | 4 | 13/109 | 12 | 9/128 | 7 | 13/109 | 12 | 7/92 | 8 | N/A | N/A | N/A | N/A |
| Meropenem | 17/18 | 94 | N/A | N/A | N/A | N/A | 4/59 | 7 | 1/42 | 2 | 1/64 | 2 | N/A | N/A | N/A | N/A |
| Piperacillin-tazobactam | N/A | N/A | N/A | N/A | 3/13 | 23 | 11/99 | 11 | 14/88 | 16 | 25/66 | 38 | N/A | N/A | N/A | N/A |
| Penicillin | 105/106 | 99 | 58/65 | 89 | 6/22 | 27 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Rifampin | 2/64 | 3 | 0/20 | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Trimethoprim-sulfamethoxazole | 91/183 | 50 | 4/102 | 4 | 0/1 | 0 | 13/102 | 13 | 37/84 | 44 | 12/69 | 17 | N/A | N/A | N/A | N/A |
| Tobramycin | N/A | N/A | N/A | N/A | N/A | N/A | 7/106 | 7 | 4/99 | 4 | 4/77 | 5 | N/A | N/A | N/A | N/A |
| Vancomycin | 0/28 | 0 | 1/114 | 1 | 51/313 | 16 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Amphotericin B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0/24 | 0 | 0/18 | 0 |
| Caspofungin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0/35 | 0 | 1/56 | 2 |
| Fluconazole | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1/107 | 1 | 24/93 | 26 |
Abbreviations: C. albicans, Candida albicans; E. coli, Escherichia coli; N/A, not available; S. aureus, Staphylococcus aureus
a Antibiotic/organism combinations with fewer than six tests were excluded
b Coagulase-negative staphylococci included S. lugdunensis, S. haemolyticus, S. epidermidis, S. capitis, S. hominis and S. warneri
c Included methicillin-susceptible S. aureus and methicillin-resistant S. aureus
d Other Candida spp. included C. dubliniensis, C. glabrata, C. krusei, C. lusitaniae, C. parapsilosis, and C. tropicalis